Your browser version may not work well with NCBI's Web applications. More information here...
1: Cochrane Database Syst Rev. 2000;(2):CD000124.Click here to read Links

Lobeline for smoking cessation.

Stead LF, Hughes JR.

ICRF General Practice Research Group, Division of Public Health and Primary Health Care, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF. lindsay.stead@dphpc.ox.ac.uk

BACKGROUND: Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking. OBJECTIVES: The objective of this review was to assess the effects of lobeline on long term smoking cessation. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register. SELECTION CRITERIA: Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up. MAIN RESULTS: We identified no trials meeting the full inclusion criteria including long term follow-up. REVIEWER'S CONCLUSIONS: There is no evidence available from long term trials that lobeline can aid smoking cessation.

PMID: 10796490 [PubMed - indexed for MEDLINE]

Recent Activity